pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,597 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT774Endpoints578BioPharma Dive223onclive165BioSpace52Fierce Biotech52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • There are already more U.S. measles cases this year than in all of 2025
    The number of measles cases in the U.S. has surpassed the record-breaking tally for all of 2025, with five more months of 2026 still to come.
    STAT · 43m ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.
    STAT · 59m ago↗ source
  • Sanofi halts development of troubled immune drug in eczema
    <figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…
    BioPharma Dive
← prev
page 1 of 64
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1h ago
↗ source
  • Ipsen’s Bylvay fails key trial in children with rare liver disease
    Ipsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies. Babies with the disease can get a Kasai proc…
    Endpoints · 1h ago↗ source
  • Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
    LONDON — One of the most anticipated Alzheimer’s studies in the past few years has created both enthusiasm and confusion, according to conversations Endpoints News recently had with about 20 scient…
    Endpoints · 2h ago↗ source
  • Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
    Plus news about Abbvie and Genmab, Johnson & Johnson and Mannkind. Novo urges court to block Lilly’s GLP-1 ads: Novo Nordisk asked a New Jersey federal court on Friday to temporarily block wh…
    Endpoints · 2h ago↗ source
  • STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
    Sanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout
    STAT · 3h ago↗ source
  • STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
    In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugs
    STAT · 3h ago↗ source
  • CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
    Minoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in Europe almost two years…
    Endpoints · 3h ago↗ source
  • Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 3h ago↗ source
  • A new, separate outbreak of the diarrhea-causing parasite
    A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
    STAT · 4h ago↗ source
  • Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67
    Michael Ehlers left his CEO role at Ascidian Therapeutics, the exon editing company he co-founded, to run R&D at the AI biotech Formation Bio. It’s not often that biotech executives leave ...
    Endpoints · 5h ago↗ source
  • STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
    Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.
    STAT · 6h ago↗ source
  • Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
    Sanofi has decided to stop working on a drug for eczema it had hoped would be a successor to its immunological mega-blockbuster Dupixent. The French pharma said that it won’t seek ...
    Endpoints · 6h ago↗ source
  • Opinion: I may be one of the last middle-class medical students who could afford to become a doctor
    A federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.
    STAT · 8h ago↗ source
  • Opinion: The U.S. pharmaceutical supply chain problem is not about China
    The national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction, writes Pooja Yerramilli.
    STAT · 8h ago↗ source
  • Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
    Unexpected alliances among Republicans and Democrats were on display over a bill meant to rein in ultra-processed foods.
    STAT · 8h ago↗ source
  • STAT+: White House offers its science blueprint: More AI, less life sciences
    The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.
    STAT · 8h ago↗ source
  • Gene editor Scribe starts second-half IPO spree with $129M listing
    A nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 million
    Endpoints · 14h ago↗ source
  • Scribe secures $129M in a rare gene editing IPO
    <figure><div><img src="https://imgproxy.divecdn.com/v0D5Ajbuzjf7G4SQRuR5yVFGXoGWXxkevKZwUQRcJjs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTU2MTc2MTM5LmpwZ…
    BioPharma Dive · 15h ago↗ source
  • FDA panel endorses broader use of certain peptides
    <figure><div><img src="https://imgproxy.divecdn.com/d2JyuXgmLsPVrlZlLVlPLECICsiII5W1r34tQBQf49c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNTIwX0w2O…
    BioPharma Dive · 16h ago↗ source
  • STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
    The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
    STAT · 20h ago↗ source
  • FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
    An FDA advisory committee voted Thursday to recommend expanding access to a popular peptide used by health and wellness enthusiasts for repairing muscles and healing injuries. The recommendation se…
    Endpoints · 22h ago↗ source
  • FDA to end pilot aimed at preventing production issues
    The FDA said it will end a pilot that was intended to help drugmakers proactively address production issues. Few companies took advantage of the program during its three-year run. In April 2027,…
    Endpoints · 22h ago↗ source
  • U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
    Federal health officials are investigating a new outbreak involving the diarrhea-causing parasite cyclospora.
    STAT · 23h ago↗ source